YXYing Xia

Ying Xia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ying Xia has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • MicroRNA-483-5p accentuates cisplatin-induced acute kidney injury by targeting GPX3

    by Ying Xia, Wenbin Pan, Xiao Xiao, Xuejuan Zhou, Wenqing Gu, Yaqin Liu, Yanyan Zhao, Lixia Li, Chenghao Zheng, Jun Liu, et al.


  • Open Access

    Safety of long-acting beta agonists and inhaled corticosteroids in children and adolescents with asthma

    by Ying Xia, Christina M. L. Kelton, Liang Xue, Jeff J. Guo, Boyang Bian, Patricia R. Wigle

    The introduction of long-acting beta agonists (LABAs) was considered a major advance in bronchodilator therapy for adult, as well as pediatric, patients with asthma. However, the use of LABAs has raised safety concerns, especially the potential for severe asthma exacerbations (SAEs) resulting in hospitalizations or even death. Meanwhile, the use of inhaled corticosteroids (ICSs), a cornerstone in the treatment of mild-to-severe persistent asthma, has been associated with growth suppression in children. The purpose of this review was to identify and discuss the major published safety studies surrounding LABA, ICS, and combined LABA/ICS usage in children. By way of a critical search for influential published clinical trials, meta-analyses, and observational studies, six studies relevant to the safety of LABA monotherapy, seven studies relevant to ICS monotherapy, and four studies on the subject of LABA/ICS combination usage were identified and reviewed. Based on the reviewed literature, the controversy surrounding these anti-asthma medications was clearly exposed. On the one hand, there is some evidence that LABA monotherapy may be associated with SAEs and asthma-related death, while ICS monotherapy may be associated with a higher risk of growth suppression. On the other hand, the concurrent use of a LABA with an ICS has been associated with positive outcomes including symptom reduction and reduced rate and severity of exacerbations. Further clinical research is warranted and has been called for by the US Food and Drug Administration.